Literature DB >> 17869098

A novel class of Hsp90 inhibitors isolated by structure-based virtual screening.

Hwangseo Park1, Yun-Jung Kim, Ji-Sook Hahn.   

Abstract

A novel class of 3-phenyl-2-styryl-3H-quinazolin-4-one Hsp90 inhibitors with in vitro anti-tumor activity are identified by structure-based virtual screening of a chemical database with docking simulations in the N-terminal ATP-binding site, in vitro ATPase assay using yeast Hsp90, and cell-based Her2 degradation assay in a consecutive fashion. These results exemplify the usefulness of the structure-based virtual screening with molecular docking in drug discovery. The structural features responsible for a tight binding of the inhibitors in the active site of Hsp90 are discussed in detail.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17869098     DOI: 10.1016/j.bmcl.2007.08.069

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  12 in total

1.  Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment.

Authors:  Hardik J Patel; Shanu Modi; Gabriela Chiosis; Tony Taldone
Journal:  Expert Opin Drug Discov       Date:  2011-05       Impact factor: 6.098

Review 2.  The Chemical Biology of Molecular Chaperones--Implications for Modulation of Proteostasis.

Authors:  Kristoffer R Brandvold; Richard I Morimoto
Journal:  J Mol Biol       Date:  2015-05-21       Impact factor: 5.469

3.  Application of docking-based comparative intermolecular contacts analysis to validate Hsp90α docking studies and subsequent in silico screening for inhibitors.

Authors:  Mahmoud A Al-Sha'er; Mutasem O Taha
Journal:  J Mol Model       Date:  2012-06-16       Impact factor: 1.810

4.  Styryl quinazolinones and its ethynyl derivatives induce myeloid differentiation.

Authors:  Sridhar Radhakrishnan; Riyaz Syed; Hisashi Takei; Ikei S Kobayashi; Eugene Nakamura; Farheen Sultana; Ahmed Kamal; Daniel G Tenen; Susumu S Kobayashi
Journal:  Bioorg Med Chem Lett       Date:  2019-06-20       Impact factor: 2.823

Review 5.  New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential.

Authors:  Yanyan Li; Tao Zhang; Steven J Schwartz; Duxin Sun
Journal:  Drug Resist Updat       Date:  2009 Feb-Apr       Impact factor: 18.500

Review 6.  Discovery and development of heat shock protein 90 inhibitors.

Authors:  Tony Taldone; Weilin Sun; Gabriela Chiosis
Journal:  Bioorg Med Chem       Date:  2008-11-06       Impact factor: 3.641

7.  Hsp90 (heat shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo.

Authors:  Bonnie Tillotson; Kelly Slocum; John Coco; Nigel Whitebread; Brian Thomas; Kip A West; John MacDougall; Jie Ge; Janid A Ali; Vito J Palombella; Emmanuel Normant; Julian Adams; Christian C Fritz
Journal:  J Biol Chem       Date:  2010-10-12       Impact factor: 5.157

8.  Molecular docking and pharmacophore studies of heterocyclic compounds as Heat shock protein 90 (Hsp90) Inhibitors.

Authors:  Suby T Baby; Shailendra Sharma; Sreenivas Enaganti; P Roby Cherian
Journal:  Bioinformation       Date:  2016-06-15

9.  Structural ensemble-based docking simulation and biophysical studies discovered new inhibitors of Hsp90 N-terminal domain.

Authors:  Hyun-Hwi Kim; Ja-Shil Hyun; Joonhyeok Choi; Kwang-Eun Choi; Jun-Goo Jee; Sung Jean Park
Journal:  Sci Rep       Date:  2018-01-10       Impact factor: 4.379

10.  Crystal structure of 3-(4-hy-droxy-phen-yl)-2-[(E)-2-phenyl-ethen-yl]quinazolin-4(3H)-one.

Authors:  Inese Mierina; Dmitrijs Stepanovs; Jolita Kuginyte; Artur Janichev; Mara Jure
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2016-03-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.